The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.
1 report, 1 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Nuvation Bio Inc. observed therapeutic responses in trials and is conducting a Phase 2 J201 study in Japan for its drug Safusidenib.Sub-event
EMA is evaluating experimental treatments developed in Japan.1 source
Keep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Alvotech submitted a regulatory application to the European Medicines Agency (EMA).
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- EMA adopted a positive opinion for Sobi's drug, with the European Commission set to confirm the decision.
- PolyPid Ltd's product received FDA Priority Review and gained single authorization across EU states from the EMA.